UM LAPs- U10 Grant

描述（由申请人提供）：密歇根大学（UM），包括其综合癌症中心（UMCCC）和医学院部门，要求其首届UI 0奖作为NCI国家临床试验网络领先的学术参与网站（NCTN LAPS-U10）。我们认为这个机会是我们机构大型癌症研究工作的重要组成部分。我们仍然致力于多机构合作对癌症治疗的进步至关重要的概念。作为一个研究中心，我们的目标是为NCTN研究和改善癌症治疗做出重要的科学、管理和患者数据贡献。NCTN过程包括收集患者数据，采用统一的毒性和反应标准，以及进行有目的的临床试验。合作小组研究是唯一的设置，在其中复杂的概念，综合方式和跨学科治疗以及辅助治疗可以得到适当的评价。合作小组还提供了更好的理解预后因素，治疗和患者的结果之间的重要关系，否则无法获得。

DESCRIPTION (provided by applicant): The University of Michigan (UM), inclusive of its Comprehensive Cancer Center (UMCCC) and Medical School Departments, requests its inaugural UI0 award as an NCI National Clinical Trials Network Lead Academic Participating Site (NCTN LAPS-U10). We view this opportunity as an important component of a large cancer research effort at our institution. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer treatment. Our goal as a LAP Site is to make significant scientific, administrative and patient data contributions to the NCTN effort to study and improve cancer therapy. The NCTN process involves the collection of patient data, adoption of uniform toxicity and response criteria, and conduction of purposeful clinical trials. Cooperative group research is the only setting in which sophisticated concepts of combined modality and interdisciplinary therapy as well as adjuvant therapies can be properly evaluated. The cooperative groups have also provided improved understanding of the important relationships between prognostic factors, therapy and patient outcomes that could not have been obtained otherwise.